Phibro Animal Health to acquire Zoetis medicated feed additive portfolio
With this divestiture, Zoetis can focus its livestock investments in other solutions, including vaccine, biologic and genetic programs.
Stay updated with breaking news from Jackc Bendheim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With this divestiture, Zoetis can focus its livestock investments in other solutions, including vaccine, biologic and genetic programs.
$350 million sale expected in second half of 2024
Zoetis Inc. and Phibro Animal Health Corporation today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive ...
Operator: Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.
Operator Good day, and thank you for standing by. Welcome to the Phibro Animal Health Corporation Q3 2021 Conference Call. [Operator Instructions] I would now like to hand the conference over to Damian Finio, Chief Financial Officer. Please go ahead. Damian Finio -- Chief Financial Officer Thank you, Tabitha. Good morning, and welcome to the Phibro Animal Health earnings call for our third quarter ended March 31, 2021. I am Damian Finio, Chief Financial Officer of Phibro. And I'm joined on today's call by Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer; as well as Don...